Verition Fund Management
PBE icon

Verition Fund Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Verition Fund Management’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-8,563
Closed -$396K – 583
2014
Q3 		$396K Buy
8,563
+1,668
+24% +$75.1K 0.06% 308
2014
Q2 		$301K Sell
6,895
-14,744
-68% -$597K 0.03% 408
2014
Q1 		$901K Buy
+21,639
New +$926K 0.14% 104

Other funds holding PBE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TAM
Trillium Asset Management Boston, Massachusetts $3.01B AUM 19.96% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SAM
SignalPoint Asset Management Springfield, Missouri $411M AUM 23.81% 1-Year Est. Return
HBT
Hills Bank & Trust North Liberty, Iowa $2.07B AUM 13.46% 1-Year Est. Return

Verition Fund Management's PBE Position: Q4 2014 in Review

Verition Fund Management sold out of Invesco Biotechnology & Genome ETF (PBE) in Q4 2014, closing a stake of 8,563 shares — an estimated $396K sold.

Verition Fund Management first reported a position in PBE in Q1 2014 and held it in 3 quarters. The position peaked at $901K in Q1 2014. 82 funds tracked by Wall St. Rank hold PBE as of Q4 2014.

  • Verition Fund Management reported no remaining Invesco Biotechnology & Genome ETF position as of Q4 2014 after selling out during the quarter.
  • Verition Fund Management sold 8,563 Invesco Biotechnology & Genome ETF shares in Q4 2014, an estimated $396K.
  • Verition Fund Management first reported a position in Invesco Biotechnology & Genome ETF in Q1 2014 and held it in 3 quarters.
  • Verition Fund Management's Invesco Biotechnology & Genome ETF position peaked at $901K in Q1 2014.
  • 82 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q4 2014.

Based on Verition Fund Management's 13F filing for Q4 2014, filed 13 Feb 2015.